Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593)

NCT03715205 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung
Melanoma

Interventions

DRUG: Pembrolizumab

Sponsor

Merck Sharp & Dohme LLC